PBM Reform Pulled Back in Late Change to Spending Package
Drug Topics
DECEMBER 20, 2024
With pressure from the House GOP, expected PBM reform was not included in Congress end-of-year spending package.
Fri.Dec 20, 2024
551 
STAT+: Next-gen obesity treatment from Novo Nordisk misses mark in pivotal trial
STAT
DECEMBER 20, 2024
Novo Nordisk’s next-generation obesity candidate led patients to lose a substantial amount of weight in a pivotal study but fell short of expectations, results that cast into doubt the future competitiveness of the company in the booming weight loss market. The treatment, called CagriSema, led patients to lose 20% of their weight at 68 weeks in a late-stage study when looking at all participants, including those who dropped out, Novo said Friday.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
First Severe Case of Bird Flu Detected in Louisiana
Drug Topics
DECEMBER 20, 2024
Recent upticks of the bird flu virus in both dairy cattle and humans have also led to a state of emergency in California.
Can you drink while taking metoprolol?
The Checkup by Singlecare
DECEMBER 20, 2024
Mixing alcohol with metoprolol can come with various side effects, some of which can be serious. Many people take metoprolol, either as metoprolol tartrate or metoprolol succinate , to help manage high blood pressure and heart conditions. If youre considering drinking alcohol while taking this prescription drug, you should know the possible risks. For some people who know how they react to the medication and alcohol, drinking in moderation may be doable.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
FDA Approves Tirzepatide for Obstructive Sleep Apnea in Patients with Obesity
Drug Topics
DECEMBER 20, 2024
Zepbound from Eli Lilly is the first and only prescription medicine approved by the FDA for adults with obstructive sleep apnea and obesity.
STAT+: Pharmalittle: We’re reading about the end of a Lilly drug shortage, a Novo obesity trial disappointment, and more
STAT
DECEMBER 20, 2024
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still shaping up, but we do foresee a few developments, such as promenading the official mascots, hanging with one of our short people, and escorting Mrs. Pharmalot to a house party or two.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
10 of our most read articles of 2024
PharmaVoice
DECEMBER 20, 2024
The high drama of an election year, industry layoffs, patent cliff strategies and other key trends that shaped pharma in 2024.
CagriSema Demonstrates Statistically Significant, Superior Weight Loss Vs Placebo
Drug Topics
DECEMBER 20, 2024
Although the drug fell short of its 25% expected weight loss, results are still promising for people with overweight or obesity.
Treatment Advances for Alzheimer Disease Provide Hope
Pharmacy Times
DECEMBER 20, 2024
New mechanisms of action are proving more effective than ever, offering slowed progression.
Zepbound, Mounjaro shortages are resolved, FDA confirms
PharmaVoice
DECEMBER 20, 2024
The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a limited grace period before taking any enforcement actions.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Study: Fatal Disseminated Herpes Zoster in Immunocompetent Individuals
Pharmacy Times
DECEMBER 20, 2024
Varicella-zoster vaccination could prevent fatal outcome among individuals with disseminated herpes zoster.
Tizanidine alternatives: What can I take instead of tizanidine?
The Checkup by Singlecare
DECEMBER 20, 2024
Tizanidine is a generic prescription muscle relaxant available as brand-name Zanaflex, which is approved by the Food and Drug Administration (FDA) for treating spasticity , a condition in which muscles stiffen or tighten, preventing normal fluid movement. Tizanidine is also used off-label (for a non-FDA-approved use) for musculoskeletal pain. In addition, its sedative effects may offer relief to patients with insomnia caused by severe muscle spasms (but this benefit is also not FDA approved).
Study: Predictive Screening Models Less Likely to Widen Existing Health Disparities in PMAD Diagnosis
Pharmacy Times
DECEMBER 20, 2024
The findings show a need for researchers and health care professionals to consider model designs to minimize disparities when diagnosing perinatal mood and anxiety disorders (PMADs).
Fierce Healthcare - Untitled Article
Fierce Healthcare
DECEMBER 20, 2024
HHS released a list of 64 drugs on Friday that will have reduced co-insurance for patients with Medicare Part B. The discounts come from the Inflation Reduction Act which requires drug makers to give rebates to the federal government when a drug's cost rises more than inflation.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
FDA Affirms Decision on Tirzepatide Shortage Resolved, Sets Transition Period for Compounding
Pharmacy Times
DECEMBER 20, 2024
Compounding pharmacies have a 60- to 90-day grace period to complete production as it continues to monitor supply and demand.
Fierce Healthcare - Untitled Article
Fierce Healthcare
DECEMBER 20, 2024
Smart ring maker Oura pocketed an additional $125 million following a $75 million investment from medical device maker Dexcom last month. | Smart ring maker Oura pocketed an additional $125 million following a $75 million investment from medical device maker Dexcom last month.
FDA Approves Expanded Use for Trikafta in Cystic Fibrosis
Pharmacy Times
DECEMBER 20, 2024
Vanzacaftor/tezacaftor/deutivacaftor (Alyftek) also received approval for the treatment of cystic fibrosis in people 6 years and older who have at least 1 F508del mutation.
Fierce Healthcare - Untitled Article
Fierce Healthcare
DECEMBER 20, 2024
Ascension's May 8 cyberattack exposed personal information from 5.6 million patients and associates of the system. While it has been suspected since June that hackers obtained the personal information of patients and employees, the system revealed Friday that bank account numbers and addresses were stolen.
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
ASHP Midyear: New Oral Treatment, Antibody Drug Conjugates Offer Additional Options for Breast Cancer
Pharmacy Times
DECEMBER 20, 2024
Pharmacists identify appropriate patients for new oral and antibody drug conjugate treatments and provide counseling to help patients navigate the evolving treatment landscape.
Fierce Healthcare - Untitled Article
Fierce Healthcare
DECEMBER 20, 2024
Epic Systems is asking a district court to throw out Particle Health's antitrust lawsuit, arguing that the startup failed to present the electronic health record company's anticompetitive conduct in its suit.
FDA Approves Expanded Indication for Setmelanotide to Include Patients 2 and Older
Pharmacy Times
DECEMBER 20, 2024
Setmelanotide is indicated to reduce excess body weight and maintain weight reduction long-term for patients with syndromic or monogenic obesity due to Bardet-Biedl syndrome.
Fierce Healthcare - Untitled Article
Fierce Healthcare
DECEMBER 20, 2024
The accreditation evaluated, over 18 months, how well Maven complies with standards across multiple categories. The distinction validates the company's ability to deliver equitable outcomes, executives said.
FDA Approves Tirzepatide as First Treatment for Moderate-to-Severe Obstructive Sleep Apnea in Adults With Obesity
Pharmacy Times
DECEMBER 20, 2024
The new approval continues to expand the therapeutic potential of GLP-1 medications such as tirzepatide, now being deemed effective in patients with obstructive sleep apnea.
Novo Nordisk takes a hit as CagriSema underperforms in weight loss
Pharmaceutical Technology
DECEMBER 20, 2024
Novo Nordisk has announced positive results from its Phase III trial of CagriSema but fell short of a previously promised 25% weight loss.
FDA Approves Symvess for Treatment of Extremity Vascular Trauma
Pharmacy Times
DECEMBER 20, 2024
The approval follows positive results from the V005 (NCT03005418) clinical trial.
FDA confirms end of Eli Lilly’s tirzepatide shortage after re-evaluation
Pharmaceutical Technology
DECEMBER 20, 2024
The US Food and Drug Administration (FDA) has stood by an earlier decision confirming that the tirzepatide shortage is over.
FDA Approves Olezarsen as Adjunct to Diet for Familial Chylomicronemia Syndrome
Pharmacy Times
DECEMBER 20, 2024
The rare genetic disease is a severe hypertriglyceridemia that can lead to potentially life-threatening acute pancreatitis.
Astellas and Sangamo sign capsid deal for neurological diseases
Pharmaceutical Technology
DECEMBER 20, 2024
Astellas Pharma and Sangamo have signed a licence agreement for neurotropic adeno-associated virus (AAV) capsid, STAC-BBB.
Women With History of Gestational Diabetes Found to Have Less Inflammatory Diets
Pharmacy Times
DECEMBER 20, 2024
This could be attributed to improved diet and health awareness.
FDA approves Ionis’ TRYNGOLZA for FCS treatment
Pharmaceutical Technology
DECEMBER 20, 2024
The US FDA has approved Ionis' TRYNGOLZA (olezarsen) as an adjunct to diet for reducing triglyceride levels in the adult population with FCS
Examining the 505(b)(2) Pathway and Implementation into EHR
Pharmacy Times
DECEMBER 20, 2024
A panelist discusses how the 505(b)(2) regulatory pathway provides a streamlined approval process for modified versions of previously approved drugs, allowing pharmaceutical companies to rely partly on existing safety/efficacy data while still requiring new clinical data, commonly used across various therapeutic areas including reformulations, new dosage forms, and drug combinations.
Palleon and Shanghai Henlius Biotech link on autoimmune therapy
Pharmaceutical Technology
DECEMBER 20, 2024
Palleon and Henlius Biotech have entered into a licence agreement and partnership for the formers E-602 to treat autoimmune diseases.
Encorafenib With Cetuximab and mFOLFOX6 Receives Accelerated Approval for Patients With Metastatic Colorectal Cancer
Pharmacy Times
DECEMBER 20, 2024
The decision is based off favorable results from the BREAKWATER trial.
Let's personalize your content